{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, and its mutations (e.g., R1441C, G2019S, I2020T) impair kinase activity, reducing Akt1 phosphorylation (Ser473) and contributing to neurodegeneration.",
          "decision": "YES"
        },
        {
          "step_name": "Step 2: Applicability of the assay",
          "extracted_paper_info": "Kinase assays and pull-down experiments were used to demonstrate reduced Akt1 phosphorylation and interaction for the variants, which are directly relevant to LRRK2’s pathogenic mechanism in Parkinson’s disease.",
          "decision": "YES"
        },
        {
          "step_name": "Step 3a: Basic controls/replicates",
          "extracted_paper_info": "The study mentions using recombinant proteins and intact cells but does not explicitly describe controls (e.g., wild-type vs. mutant) or experimental repetition (e.g., \"n=3\").",
          "decision": "NO"
        },
        {
          "step_name": "Step 3b: Accepted/validated assay",
          "extracted_paper_info": "Kinase assays and pull-down experiments are standard techniques in the field and have been historically validated in prior studies.",
          "decision": "YES"
        },
        {
          "step_name": "Step 4b: No OddsPath calculation",
          "extracted_paper_info": "The paper does not provide statistical analyses (e.g., p-values, OddsPath) or quantify the number of control variants tested for this specific assay.",
          "decision": "NO"
        }
      ],
      "final_evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, and its mutations (e.g., R1441C, G2019S, I2020T) impair kinase activity, reducing Akt1 phosphorylation (Ser473) and contributing to neurodegeneration.",
          "decision": "YES"
        },
        {
          "step_name": "Step 2: Applicability of the assay",
          "extracted_paper_info": "Kinase assays and pull-down experiments were used to demonstrate reduced Akt1 phosphorylation and interaction for the variants, which are directly relevant to LRRK2’s pathogenic mechanism in Parkinson’s disease.",
          "decision": "YES"
        },
        {
          "step_name": "Step 3a: Basic controls/replicates",
          "extracted_paper_info": "The study mentions using recombinant proteins and intact cells but does not explicitly describe controls (e.g., wild-type vs. mutant) or experimental repetition (e.g., \"n=3\").",
          "decision": "NO"
        },
        {
          "step_name": "Step 3b: Accepted/validated assay",
          "extracted_paper_info": "Kinase assays and pull-down experiments are standard techniques in the field and have been historically validated in prior studies.",
          "decision": "YES"
        },
        {
          "step_name": "Step 4b: No OddsPath calculation",
          "extracted_paper_info": "The paper does not provide statistical analyses (e.g., p-values, OddsPath) or quantify the number of control variants tested for this specific assay.",
          "decision": "NO"
        }
      ],
      "final_evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson’s disease, and its mutations (e.g., R1441C, G2019S, I2020T) impair kinase activity, reducing Akt1 phosphorylation (Ser473) and contributing to neurodegeneration.",
          "decision": "YES"
        },
        {
          "step_name": "Step 2: Applicability of the assay",
          "extracted_paper_info": "Kinase assays and pull-down experiments were used to demonstrate reduced Akt1 phosphorylation and interaction for the variants, which are directly relevant to LRRK2’s pathogenic mechanism in Parkinson’s disease.",
          "decision": "YES"
        },
        {
          "step_name": "Step 3a: Basic controls/replicates",
          "extracted_paper_info": "The study mentions using recombinant proteins and intact cells but does not explicitly describe controls (e.g., wild-type vs. mutant) or experimental repetition (e.g., \"n=3\").",
          "decision": "NO"
        },
        {
          "step_name": "Step 3b: Accepted/validated assay",
          "extracted_paper_info": "Kinase assays and pull-down experiments are standard techniques in the field and have been historically validated in prior studies.",
          "decision": "YES"
        },
        {
          "step_name": "Step 4b: No OddsPath calculation",
          "extracted_paper_info": "The paper does not provide statistical analyses (e.g., p-values, OddsPath) or quantify the number of control variants tested for this specific assay.",
          "decision": "NO"
        }
      ],
      "final_evidence_strength": "PS3_supporting"
    }
  ]
}